2023
Patient-Reported and Toxicity Results from the FABREC Study: A Multicenter Randomized Trial of Hypofractionated vs. Conventionally-Fractionated Postmastectomy Radiation Therapy after Implant-Based Reconstruction
Wong J, Uno H, Tramontano A, Pellegrini C, Bellon J, Cheney M, Hardenbergh P, Ho A, Horst K, Kim J, Leonard K, Moran M, Park C, Recht A, Shiloh R, Taghian A, Warren L, Wright J, Chun Y, Punglia R. Patient-Reported and Toxicity Results from the FABREC Study: A Multicenter Randomized Trial of Hypofractionated vs. Conventionally-Fractionated Postmastectomy Radiation Therapy after Implant-Based Reconstruction. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e3-e4. DOI: 10.1016/j.ijrobp.2023.08.029.Peer-Reviewed Original ResearchPreoperative endocrine therapyCW toxicityEndocrine therapyQuality-of-lifeLymph nodesHF-PMRTRadiation therapyBreast reconstructionRandomized trialsResults Median follow-upChest wallTissue expanderImplant-based breast reconstructionImmediate prosthetic reconstructionPostmastectomy radiation therapyCompare quality-of-lifeMedian follow-upImplant-based reconstructionPost-operative infectionPlacement of tissue expandersMulticenter randomized trialQuality-of-life scoresSide effects of treatmentStage 0-III breast cancerPhysical well-being scores
2014
Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?
Moran MS. Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making? American Society Of Clinical Oncology Educational Book 2014, e32-6. PMID: 24857120, DOI: 10.14694/edbook_am.2014.34.e32.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerLocal-regional relapseBreast cancer therapySporadic triple-negative breast cancerBreast cancerEarly-stage triple-negative breast cancerYounger ageAggressive biologic characteristicsBreast conservation approachHER2-positive subgroupContralateral breast cancerWhole breast irradiationDefinitive treatment strategyNegative breast cancer subtypeHypothesis-generating dataPartial breast irradiationBreast cancer subtypesBRCA1 mutation carriersSystemic chemotherapyAdvanced diseaseRandomized trialsGuideline recommendationsLuminal tumorsBreast irradiationTNBC subtypes
2009
Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy.
Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Garber J, Merajver S, Balmanya J, Meirovitz A, Domchek S. Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy. Cancer Research 2009, 69: 959-959. DOI: 10.1158/0008-5472.sabcs-09-959.Peer-Reviewed Original ResearchContralateral breast cancerOperable breast cancerBreast conservationBreast cancerLocal therapyBRCA1/2 mutationsDistant failureClinical characteristicsBRCA1/2 carriersLocal failureBC-specific survivalDeleterious BRCA1/2 mutationsLocal treatment optionsInvasive lobular cancerGermline BRCA1/2 mutationsSignificant predictorsSignificant differencesOnly significant predictorAdjuvant chemotherapyBCT patientsOverall survivalContralateral breastLobular cancerLocal recurrenceRandomized trials